Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Aug 1;245(3):296-301.
doi: 10.2460/javma.245.3.296.

Use of trazodone to facilitate postsurgical confinement in dogs

Affiliations
Clinical Trial

Use of trazodone to facilitate postsurgical confinement in dogs

Margaret E Gruen et al. J Am Vet Med Assoc. .

Abstract

Objective: To investigate the safety and efficacy of oral administration of the serotonin antagonist and reuptake inhibitor trazodone hydrochloride to facilitate confinement and calming after orthopedic surgery in dogs.

Design: Prospective open-label clinical trial.

Animals: 36 client-owned dogs that underwent orthopedic surgery.

Procedures: Starting the day after surgery, dogs were administered trazodone (approx 3.5 mg/kg [1.6 mg/lb], PO, q 12 h) with tramadol (4 to 6 mg/kg [1.8 to 2.7 mg/lb], PO, q 8 to 12 h) for pain management. After 3 days, administration of tramadol was discontinued, and the trazodone dosage was increased (approx 7 mg/kg [3.2 mg/lb], PO, q 12 h) and maintained for at least 4 weeks. If needed, trazodone dosage was increased (7 to 10 mg/kg [3.2 to 4.5 mg/lb], PO, q 8 h). Owners completed electronic surveys rating their dogs' confinement tolerance, calmness or hyperactivity level, and responses to specific provocative situations prior to surgery and 1, 2, 3, and 4 weeks after surgery and at the postsurgery evaluation (at 8 to 12 weeks).

Results: Most (32/36 [89%]) of owners reported that their dogs, when given trazodone during the 8 to 12 weeks following orthopedic surgery, improved moderately or extremely with regard to confinement tolerance and calmness. Trazodone was well tolerated, even in combination with NSAIDs, antimicrobials, and other medications; no dogs were withdrawn from the study because of adverse reactions. Owner-reported median onset of action of trazodone was 31 to 45 minutes, and median duration of action was ≥ 4 hours.

Conclusions and clinical relevance: Results suggested that oral administration of trazodone was safe and efficacious and may be used to facilitate confinement and enhance behavioral calmness of dogs during the critical recovery period following orthopedic surgery.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Latency to trazodone effect per client report at the final survey. The greatest percent of clients reported the effect of trazodone was observed within 31–45 minutes of administration. Over 90% percent of clients reported latency of effect between 16–90 minutes.
Figure 2
Figure 2
Duration of trazodone effect per client report at the final survey. The majority of clients reported duration of behavioral effect of trazodone to be 4 or more hours.
Figure 3
Figure 3
Client’s evaluation of the helpfulness of trazodone treatment on confinement tolerance and calming at the final survey. Percent of owners providing each response is shown.

Comment in

References

    1. Guthrie JW, Keeley BJ, Maddock E, et al. Effect of signalment on the presentation of canine patients suffering from cranial cruciate ligament disease. J Sm Anim Prac. 2012;53(5):273–277. - PubMed
    1. Knudsen CS, Arthurs GI, Hayes GM, Langley-Hobbs SJ. Long bone fracture as a complication following external skeletal fixation: 11 cases. J Sm Anim Prac. 2012;53:687–692. - PubMed
    1. Hofmeister EH, Chandler MJ, Read MR. Effects of acepromazine, hydromorphone, or an acepromazine-hydromorphone combination on the degree of sedation in clinically normal dogs. J Am Vet Med Assoc. 2010;237(19):1155–1159. - PubMed
    1. Plumb DC. Plumb’s veterinary drug handbook. 7. Ames, IA: John Wiley and Sons, Inc; 2011.
    1. DeBattista C, Sofuoglu M, Schatzberg A. Serotonergic synergism: the risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs. Biol Psychiatry. 1998;44:341–347. - PubMed

Publication types